21 hasil untuk "Adam, Kieran"
Menampilkan 1–20 · 0,85 detik · RSS
-
Artikel Jurnal Teks lengkap
Immunohistochemistry of Immune Cells and Cells Bound to in vivo Administered Antibodies in Liver, Lung, Pancreas, and Colon of B6/lpr Mice
Employing a novel mouse model of immune related adverse events (irAEs) induced by combination of anti-PD1 and anti-CTLA-4 antibodies, we visualized immune infiltration into the liver, lung, pancreas, and colon. Here, we describe the avidin-biotin conjugate (ABC) method used to stain T cells (CD4…
-
Artikel Jurnal Teks lengkap
Data on the identification of VRK2 as a mediator of PD-1 function
Therapeutic programmed cell death protein 1 (PD-1) blockade enhances T cell mediated anti-tumor immunity, but many patients do not respond, and a significant proportion develops inflammatory toxicities. To develop better therapeutics and to understand the signaling pathways downstream of PD-1 we…
-
Artikel Jurnal Teks lengkap
A novel mouse model for checkpoint inhibitor-induced adverse events
Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of a variety of cancers, however their therapeutic potential is limited by abstruse immune related adverse events. Currently, no robust animal model exists of checkpoint inhibitor-induced adverse events…
-
Artikel Jurnal Teks lengkap
VRK2 inhibition synergizes with PD-1 blockade to improve T cell responses
Therapeutic programmed cell death protein 1 (PD-1) blockade enhances T cell mediated anti-tumor immunity but many patients do not respond and a significant proportion develops inflammatory toxicities. To develop better therapeutics and to understand the signaling pathways downstream of PD-1 we…
-
Artikel Jurnal Teks lengkap
PD-1-stimulated T cell subsets are transcriptionally and functionally distinct
Despite the obvious inhibitory outcome of PD-1 signaling, an additional series of functions are activated. We have observed that T cells stimulated through the T cell receptor (TCR) and PD-1 primarily do not proliferate; however, there is a population of cells that proliferates more than through…
-
Artikel Jurnal Teks lengkap
Transmembrane adaptor protein PAG is a mediator of PD-1 inhibitory signaling in human T cells
The inhibitory receptor PD-1 is expressed on T cells to inhibit select functions when ligated. The complete signaling mechanism downstream of PD-1 has yet to be uncovered. Here, we discovered phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG) is phosphorylated following…
-
Artikel Jurnal Teks lengkap
Advances in LAG3 cancer immunotherapeutics
Cancer treatment has entered the age of immunotherapy. Immune checkpoint inhibitor (ICI) therapy has shown robust therapeutic potential in clinical practice, with significant improvements in progression-free survival (PFS) and overall survival (OS). Recently, checkpoint blockade of the lymphocyte…
-
Artikel Jurnal Teks lengkap
Neutralization of the adaptor protein PAG by monoclonal antibody limits murine tumor growth
The transmembrane adaptor phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG) is phosphorylated in T cells downstream of PD-1 signaling and contributes to the resulting functional inhibition of multiple cellular processes. Furthermore, PAG expression is negatively…
-
Artikel Jurnal Teks lengkap
SLAMF6 clustering is required to augment T cell activation
The signaling lymphocytic activation molecule (SLAM) family is comprised of nine distinct receptors that are expressed exclusively on hematopoietic cells. Most of these transmembrane receptors are homotypic by nature and downstream signaling occurs when cells that express the same SLAM receptor…
-
Artikel Jurnal Teks lengkap
SHP2 targets ITK downstream of PD-1 to inhibit T cell function
PD-1 is a critical therapeutic target in cancer immunotherapy and antibodies blocking PD-1 are approved for multiple types of malignancies. The phosphatase SHP2 is the main effector mediating PD-1 downstream signaling and accordingly attempts have been made to target this enzyme as an alternative…
-
Artikel Jurnal Teks lengkap
Outcomes of Postchemotherapy Retroperitoneal Lymph Node Dissection from a High-volume UK Centre Compared with a National Data Set
Background: Retroperitoneal lymph node dissection (RPLND) is essential for the treatment of metastatic germ cell tumours of the testis. Recommendations on the referral and management of complex urological cancers in the UK includes centralisation of services to regional centres. Objective: To…
Juga tersedia di: PubMed Central
-
Artikel Jurnal Teks lengkap
SLAMF6 compartmentalization enhances T cell functions
Signaling lymphocyte activation molecule family member 6 (SLAMF6) is a T cell co-receptor. Previously, we showed that SLAMF6 clustering was required for T cell activation. To better understand the relationship between SLAMF6 location and function and to evaluate the role of SLAMF6 as a therapeutic…
-
Artikel Jurnal Teks lengkap
EF Hand domain family member D2 is required for T cell cytotoxicity
Programmed cell death-1 (PD-1) is a major co-inhibitory receptor and a member of the immunological synapse (IS). To uncover proteins that regulate PD-1 recruitment to the IS, we searched for cytoskeleton-related proteins that also interact with PD-1 using affinity purification mass spectrometry…
-
Artikel Jurnal Teks lengkap
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity
BACKGROUND: Immune checkpoint inhibitors (ICIs) have improved outcomes and extended patient survival in several tumor types. However, ICIs often induce immune-related adverse events (irAEs) that warrant therapy cessation, thereby limiting the overall effectiveness of this class of therapeutic…
-
Artikel Jurnal Teks lengkap
LAG3 dimerization is required for TCR/CD3 interaction and inhibition of anti-tumor immunity
Lymphocyte activation gene 3 (LAG3) is an inhibitory receptor (IR) that plays a critical role in controlling T cell tolerance, autoimmunity and is a major immunotherapeutic target. LAG3 is expressed on the cell surface as a homodimer but the functional relevance of this is unknown. Here we show…
-
Artikel Jurnal Teks lengkap
Understanding the health-related quality of life and treatment-related side-effects in patients who have been in remission from testicular cancer for 12–24 months
INTRODUCTION: Despite the excellent long-term prognosis after treatment for testicular cancer (TCa), therapy-related side effects can be persistent and severe. The aim of this study was to determine the nature and prevalence of post-treatment symptoms and their impact on health-related quality of…
Juga tersedia di: DOAJ
-
Artikel Jurnal Teks lengkap
The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals
Programmed cell death protein 1 (PD-1) is an inhibitory receptor on T lymphocytes that is critical for modulating adaptive immunity. As such, it has been successfully exploited for cancer immunotherapy. Programmed death ligand 1 (PD-L1) and PD-L2 are ligands for PD-1; the former is ubiquitously…
-
Artikel Jurnal Teks lengkap
Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions
Programmed cell death protein 1 (PD-1) is a critical inhibitory receptor that limits excessive T cell responses. Cancer cells have evolved to evade these immunoregulatory mechanisms by upregulating PD-1 ligands and preventing T cell–mediated anti-tumor responses. Consequently, therapeutic blockade…